Compare MPB & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | OBX |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 839.5M |
| IPO Year | 1996 | 2026 |
| Metric | MPB | OBX |
|---|---|---|
| Price | $36.10 | $11.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $41.00 | $39.00 |
| AVG Volume (30 Days) | 84.4K | ★ 612.3K |
| Earning Date | 10-30-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.43 | N/A |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $29.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.95 | $11.79 |
| 52 Week High | $39.15 | $39.00 |
| Indicator | MPB | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 33.11 |
| Support Level | $35.87 | N/A |
| Resistance Level | $36.32 | $18.21 |
| Average True Range (ATR) | 0.76 | 1.24 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 68.20 | 5.94 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.